JWA
KRYS icon

JFS Wealth Advisors’s Krystal Biotech KRYS Stock Holding History

JFS Wealth Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.46K Buy
12
+7
+140% +$2.09K ﹤0.01% 1320
2026
Q1 		$1.29K Buy
5
+2
+67% +$532 ﹤0.01% 1622
2025
Q4 		$740 Buy
3
+1
+50% +$210 ﹤0.01% 1751
2025
Q3 		$354 Hold
2
– – ﹤0.01% 1802
2025
Q2 		$275 Hold
2
– – ﹤0.01% 1766
2025
Q1 		$361 Hold
2
– – ﹤0.01% 1800
2024
Q4 		$314 Hold
2
– – ﹤0.01% 1823
2024
Q3 		$365 Hold
2
– – ﹤0.01% 1832
2024
Q2 		$368 Hold
2
– – ﹤0.01% 1840
2024
Q1 		$356 Hold
2
– – ﹤0.01% 1841
2023
Q4 		$249 Hold
2
– – ﹤0.01% 1883
2023
Q3 		$232 Hold
2
– – ﹤0.01% 1844
2023
Q2 		$235 Hold
2
– – ﹤0.01% 1862
2023
Q1 		$161 Buy
2
+1
+100% +$79 ﹤0.01% 1846
2022
Q4 		$79 Buy
+1
New +$74 ﹤0.01% 1895

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JFS Wealth Advisors's KRYS Position: Q2 2026 in Review

JFS Wealth Advisors increased its Krystal Biotech (KRYS) stake by 140% in Q2 2026, buying an estimated $2.09K and bringing the position to 12 shares worth $4.46K. The position accounts for ﹤0.01% of the portfolio, ranked #1320.

JFS Wealth Advisors first reported a position in KRYS in Q4 2022 and has held it in 15 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • JFS Wealth Advisors held 12 shares of Krystal Biotech worth $4.46K as of Q2 2026.
  • JFS Wealth Advisors bought 7 Krystal Biotech shares in Q2 2026, an estimated $2.09K.
  • Krystal Biotech made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q2 2026, its #1320 holding.
  • JFS Wealth Advisors first reported a position in Krystal Biotech in Q4 2022 and has held it in 15 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on JFS Wealth Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.